Hua MedicineHUMDF 46 EV-to-FCF is -16.59 as of Jun. 29, 2026. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 559 Drug Manufacturers companies, Hua Medicine ranks worse than 178890.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hua Medicine's Enterprise Value is $136.54 Mil.
Hua Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.23 Mil. Therefore, Hua Medicine's EV-to-FCF for today is -16.59.
The historical rank and industry rank for Hua Medicine's EV-to-FCF or its related term are showing as below:
HUMDF'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.95 Med: -4.76 Max: 0.93
Current: -16.5
During the past 10 years, the highest EV-to-FCF of Hua Medicine was 0.93. The lowest was -43.95. And the median was -4.76.
HUMDF's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs HUMDF: -16.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hua Medicine's PE Ratio (TTM) for today is calculated as:
Hua Medicine's share price for today is $0.3401.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.153.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hua Medicine EV-to-FCF Related Terms
Hua Medicine EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Hua Medicine's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hua Medicine's EV-to-FCF falls into.
Hua Medicine's current Enterprise Value is $136.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a EV-to-FCF of -16.59 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is Hua Medicine's EV-to-FCF too high?
Hua Medicine's current EV-to-FCF is -16.59. Based on the distribution chart, Hua Medicine ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #999999 out of 559 companies for EV-to-FCF. This places Hua Medicine in the lower half of its industry. The industry median EV-to-FCF is 20.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current EV-to-FCF is -16.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current EV-to-FCF is -16.59. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current EV-to-FCF is -16.59 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
EV-to-FCF: -16.59
GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
